TABLE 24Peginterferon alfa-2b and ribavirin, weight-based dosage

Body weight (kg)PEG α-2bRibavirin
Vial/pen strength (μg/ml)Administer once weekly (ml)Total daily dose (mg)No. of capsules (200 mg)
< 40500.58004
40–50800.58004
51–64800.58004
65–751000.510005
76–851200.510005
86–1051500.512006
> 1051500.514007

PEG α, peginterferon alfa.

From: 5, Economic analysis

Cover of Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation
Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.17.
Hartwell D, Jones J, Baxter L, et al.
Southampton (UK): NIHR Journals Library; 2011 Apr.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.